The ErbB Signaling Network and Its Potential Role in Endometrial Cancer

Endometrial cancer (EC) is the second most common malignancy of the female reproductive system worldwide. The updated EC classification emphasizes the significant role of various signaling pathways such as PIK3CA-PIK3R1-PTEN and RTK/RAS/β-catenin in EC pathogenesis. Some of these pathways are part o...

Full description

Saved in:
Bibliographic Details
Published in:Epigenomes 2023-10, Vol.7 (4), p.24
Main Authors: Androutsopoulos, Georgios, Styliara, Ioanna, Zarogianni, Evgenia, Lazurko, Nadia, Valasoulis, George, Michail, Georgios, Adonakis, Georgios
Format: Article
Language:English
Subjects:
Analysis
Apoptosis
Artificial intelligence
carcinogenesis
Causes of
Cell cycle
Cellular biology
EGF system
Endometrial cancer
Endometrium
Epidermal growth factor
ErbB protein
ErbB receptors
ErbB-2 protein
expression profile
Genetic aspects
Kinases
Ligands
Malignancy
Oncogenes
Pathogenesis
Phosphorylation
Physiological aspects
physiology
Post-menopause
Proteins
PTEN protein
Reproductive system
Review
Signal transduction
signaling pathways
Uterine cancer
β-Catenin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Endometrial cancer (EC) is the second most common malignancy of the female reproductive system worldwide. The updated EC classification emphasizes the significant role of various signaling pathways such as PIK3CA-PIK3R1-PTEN and RTK/RAS/β-catenin in EC pathogenesis. Some of these pathways are part of the EGF system signaling network, which becomes hyperactivated by various mechanisms and participates in cancer pathogenesis. In EC, the expression of ErbB receptors is significantly different, compared with the premenopausal and postmenopausal endometrium, mainly because of the increased transcriptional activity of ErbB encoding genes in EC cells. Moreover, there are some differences in ErbB-2 receptor profile among EC subgroups that could be explained by the alterations in pathophysiology and clinical behavior of various EC histologic subtypes. The fact that ErbB-2 receptor expression is more common in aggressive EC histologic subtypes (papillary serous and clear cell) could indicate a future role of ErbB-targeted therapies in well-defined EC subgroups with overexpression of ErbB receptors.
ISSN:2075-4655
2075-4655
DOI:10.3390/epigenomes7040024